# How Ipamorelin Works in the Research > How ipamorelin works: the peptide docks on the ghrelin receptor (GHS-R1a) to release a clean GH pulse. Plain-English mechanism, plus ipamorelin vs sermorelin and tesamorelin. From receptor to GH pulse to IGF-1, in plain English — and how ipamorelin differs from the GHRH-type peptides sermorelin and tesamorelin. ## The short version Here is how ipamorelin works, and it answers the common search "what does ipamorelin peptide do" directly. The peptide imitates ghrelin — the gut hormone that signals hunger — and docks onto a receptor called GHS-R1a on cells in the pituitary gland. That docking tells those cells to release a short burst of growth hormone (GH) [1]. That is the core action. What makes ipamorelin distinctive is that it does this *selectively*: it triggers GH without also raising the stress hormones cortisol and prolactin that older peptides bumped up [1]. The GH burst can then prompt the liver to make IGF-1, the messenger behind many of GH's slower effects — though in short studies that downstream IGF-1 rise did not reliably appear [4]. Below, each step is unpacked plainly, followed by how ipamorelin compares with the GHRH-type peptides. ## What is ipamorelin peptide So, what is ipamorelin peptide in one paragraph: it is a synthetic pentapeptide — a lab-made chain of five amino acids (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) — that does not occur naturally in the body. It was built by modifying an earlier peptide (GHRP-1), and a couple of unusual amino-acid building blocks make it resistant to the enzymes that would normally chew a peptide up [1]. Functionally, it is a "growth hormone secretagogue" — a compound that makes the body secrete its own GH, rather than being GH itself. That distinction matters: ipamorelin does not add growth hormone from outside; it asks the pituitary to release a pulse of the GH it already makes [1]. ## Step by step: receptor to pulse to IGF-1 **Step 1 — docking.** Ipamorelin binds GHS-R1a (the ghrelin receptor) on pituitary somatotrophs, the GH-storing cells. It fits the same lock that your natural hunger hormone ghrelin uses [1]. **Step 2 — the signal.** Binding flips on an internal relay (a Gq/PLC pathway) that raises calcium inside the cell, and the rise in calcium makes the cell release its stored GH as a pulse [1]. There is evidence part of this loop runs through the gut, too: removing the stomach lining (where the body makes ghrelin) cut GHRP-driven GH release by 60-70% in one study, suggesting these peptides partly work by prompting the body's own ghrelin [8]. **Step 3 — downstream.** The GH pulse can instruct the liver to produce IGF-1, which carries out many of GH's longer-term, tissue-level effects. But this step is conditional — short rodent studies raised bone growth without a measurable IGF-1 increase, so a single pulse does not guarantee a sustained IGF-1 rise [4]. The selectivity holds throughout: cortisol and prolactin stay flat [1]. ## Ipamorelin vs sermorelin The ipamorelin vs sermorelin comparison is really GHRP versus GHRH — two different doors into the same GH-releasing cell. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist; it triggers a GH pulse and, by design, does not raise cortisol or prolactin [1]. Sermorelin is a GHRH analog — a shortened copy of growth-hormone-releasing hormone — that works through the separate GHRH receptor. Because they act through complementary pathways, they are conceptually combinable rather than interchangeable, and class-level data show a GHRP plus GHRH drives more GH output than either alone [13]. The practical contrast: sermorelin pushes the GHRH door, ipamorelin pushes the ghrelin door, and ipamorelin's selling point within its own family is its clean hormonal selectivity [1]. Neither is FDA-approved for the wellness uses they are marketed for. ## Ipamorelin vs tesamorelin In the ipamorelin vs tesamorelin comparison, the mechanistic split is the same GHRP-versus-GHRH divide: ipamorelin is a ghrelin-receptor agonist that prompts a GH pulse [1], while tesamorelin is a stabilized GHRH analog acting on the GHRH receptor. The difference that matters most, though, is evidentiary. Tesamorelin has been studied in controlled human trials for a specific approved use, whereas ipamorelin's only human efficacy trial — for postoperative ileus — failed its primary endpoint, and it has no approved indication anywhere [3]. So comparing them is partly apples-to-oranges: one is a GHRH-type peptide with a defined clinical record in its niche, the other a selective ghrelin-mimetic whose human benefit remains unproven. They share the goal of raising GH; they differ in receptor, and they differ sharply in how far the human evidence has progressed [3]. --- A plain-English digest of the ipamorelin research — the GH-axis findings explained and cited, with no clinic, no pharmacy, and no prescription behind it.